JAFRON(SZ:300529)2024-08-09 09:25Financial Performance - The company achieved a revenue of CNY 1.496 billion in the first half of 2024, representing a growth of 47.77% compared to the same period last year [2] - Sales revenue from blood perfusion devices and adsorbers reached CNY 1.401 billion, with a year-on-year increase of 87.35% [2] - The net profit attributable to shareholders was CNY 553 million, up 99.10% year-on-year [2] - The net profit after deducting non-recurring gains and losses was CNY 526 million, reflecting a growth of 99.99% [2] - The gross profit margin for the reporting period was 80.54%, with blood perfusion devices achieving a gross margin of 84.46% [2] Market Expansion - In the nephrology sector, the company has covered over 6,000 hospitals, with perfusion device revenue growing by 84% year-on-year [3] - The liver disease sector has expanded to over 2,000 hospitals, with product revenue increasing by 112% [3] - The critical care and emergency sector has reached over 1,600 hospitals, with product revenue rising by 72% [3] Product Development - The company has obtained three product registration certificates in the nephrology field, enhancing its ability to meet the individualized treatment needs of patients [5] - The HA130 product price was reduced by 26%, leading to a 127% increase in sales volume [5] - The pHA series, the first in China to simultaneously remove protein-bound toxins and large molecular toxins, was launched in November 2023 and is currently used in over 60 clinical hospitals [6] Research and Development - R&D investment for the first half of 2024 was CNY 113 million, accounting for 7.5% of revenue [4] - The company holds 359 authorized patents, including 102 invention patents [4] Social Responsibility - The company donated CNY 15.8 million for rural revitalization and educational support projects during the reporting period [5] Shareholder Returns - In May 2024, the company distributed cash dividends totaling CNY 310 million, with a dividend payout ratio of 70% [4] - Since its IPO, the cumulative dividend has reached CNY 2.95 billion, exceeding 60% of the total raised funds [4] International Business - Overseas revenue grew by 64% in the first half of 2024, with products covering over 2,000 hospitals in 94 countries [4] - The company participated in international clinical projects, achieving recognition for its contributions in nephrology and sepsis treatment [4] Strategic Outlook - The company is optimistic about future growth despite external uncertainties, focusing on leveraging its innovative blood adsorption technology [11]